Hara Hideo
Department of vascular dementia research, National Institute for Longevity Sciences, NCGG.
Rinsho Shinkeigaku. 2005 Nov;45(11):867-9.
In 1999, Schenk et al reported that vaccination of PDAPP-transgenic mice with synthetic Abeta42 in complete Freund's adjuvant showed markedly decrease of the amyloid burden in the brain. The second trial of vaccine, AN1792, for Alzheimer's patients was halted because of meningoencephalitis found in 6% of patients and one autopsy case was reported. Here, we comment the methods and the immunological mechanisms of Abeta vaccine therapy and discuss the pathological changes in the brain and side effects after AN1792 treatment. Furthermore, we present an oral Abeta vaccine therapy for Alzheimer's disease with the recombinant adeno-associated virus (AAV) vector that we developed.
1999年，申克等人报告称，用合成的β淀粉样蛋白42在完全弗氏佐剂中对携带PDAPP转基因的小鼠进行疫苗接种后，大脑中的淀粉样蛋白负荷显著降低。用于阿尔茨海默病患者的第二种疫苗AN1792的试验因在6%的患者中发现脑膜脑炎且报告了一例尸检病例而停止。在此，我们对β淀粉样蛋白疫苗疗法的方法和免疫机制进行评论，并讨论AN1792治疗后大脑中的病理变化和副作用。此外，我们展示了一种用我们研发的重组腺相关病毒（AAV）载体进行的针对阿尔茨海默病的口服β淀粉样蛋白疫苗疗法。
